Symbols

Kura Oncology 2025 Q3 Earnings Revenue Misses Estimates by 75.72%, Net Loss Widens 36.2%

Generated by AI AgentAinvest Earnings Report DigestReviewed byAInvest News Editorial Team

Wednesday, Nov 5, 2025 5:49 pm ET1min read

KURA--

Aime Summary

- Kura OncologyKURA-- reported 2025 Q3 revenue 75.72% below estimates, with net loss widening 36.2%.

- Revenue relied solely on Kyowa Kirin partnership, highlighting lack of diversified income streams.

- CEO emphasized ziftomenib's FDA PDUFA date (Nov 30, 2025) and KOMET-017 trial progress despite rising costs.

- $30M milestone payment from Kyowa Kirin and $315M pending payments underscore ziftomenib's AML therapy potential.

- Post-earnings stock dropped sharply, with no revenue guidance provided amid ongoing operational challenges.

Kura Oncology (KURA) reported fiscal 2025 Q3 earnings on Nov 5, 2025, with results significantly below expectations. , , . , driven by collaboration revenue from its Kyowa Kirin partnership.

Revenue

, . , though the absence of diversified revenue streams highlights operational challenges.

Earnings/Net Income

, , , , in Q3 2024. , exacerbated by rising R&D and G&A expenses.

Price Action

Following the earnings report, .

Post-Earnings Price Action Review

. , , 2025, . , .

CEO Commentary

CEO Troy Wilson emphasized ziftomenib’s regulatory progress, noting the FDA’s PDUFA date remains on track for November 30, 2025. He highlighted robust clinical and commercial readiness, . , underscoring the company’s heavy investment in late-stage trials.

Guidance

Management reiterated focus on the November 30 PDUFA date and advancing KOMET-017 trials. , with no revenue targets provided.

Additional News

Kura announced a second $30 million milestone payment from Kyowa Kirin for the KOMET-017 trial, . The company plans to host a virtual investor event on December 8 to discuss ASH 2025 data updates. Analysts highlighted the $315 million in pending milestone payments and ziftomenib’s potential as a best-in-class therapy for AML.

Ainvest Earnings Report Digest

Que se dé a conocer la lista de las empresas destacadas, según sus informes de resultados, después de que cierren las bolsas hoy y antes de que abran las bolsas mañana.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments

﻿

Add a public comment...

No comments yet

AInvest
PRO

Editorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process. While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context. Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue